ARCH Venture Management, LLC holds a concentrated book of 10 stocks worth $677.1M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened GENERATE BIOMEDICINES INC and trimmed ERASCA INC. Their largest long position is MAZE THERAPEUTICS INC at 18% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1274403/holdings"
Use Arkolith to show ARCH Venture Management, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
18% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as ARCH Venture Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| FMR LLC | 10 / 10 | $1.0B |
| VANGUARD CAPITAL MANAGEMENT LLC | 10 / 10 | $551.9M |
| GEODE CAPITAL MANAGEMENT, LLC | 10 / 10 | $287.9M |
| MORGAN STANLEY | 10 / 10 | $130.3M |
| BANK OF AMERICA CORP /DE/ | 10 / 10 | $102.8M |
| JPMORGAN CHASE & CO | 10 / 10 | $87.0M |
| MILLENNIUM MANAGEMENT LLC | 10 / 10 | $83.0M |
| UBS Group AG | 10 / 10 | $80.0M |
Ranked by how many of ARCH Venture Management, LLC's top 10 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Maze Therapeutics Inc COM | $123.0M | 4.12M | 18.2% | —Held | |
| 2 | Rapport Therapeutics Inc COM | $116.7M | 3.73M | 17.2% | —Held | |
| 3 | Vir Biotechnology Inc COM | $115.7M | 12.92M | 17.1% | —Held | |
| 4 | Erasca Inc COM | $114.7M | 7.09M | 16.9% | ▼−36% Reduced · −4.0M sh | |
| 5 | Beam Therapeutics Inc COM | $108.2M | 4.54M | 16.0% | —Held | |
| 6 | Lyell Immunopharma Inc COM NEW | $65.1M | 3.25M | 9.6% | ▲+18% Added · +488K sh | |
| 7 | Generate Biomedicines Inc COM SHS | $24.3M | 1.94M | 3.6% | ▲New New position | |
| 8 | 10X Genomics Inc CL A COM | $4.6M | 217.8K | 0.7% | ▼−70% Reduced · −520K sh | |
| 9 | Gossamer Bio Inc COM | $2.6M | 8.06M | 0.4% | —Held | |
| 10 | Q32 Bio Inc COM | $2.1M | 320.5K | 0.3% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 10 | $677.1M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 9 | $651.7M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 9 | $492.4M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 11 | $299.1M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 9 | $206.2M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 9 | $230.2M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 9 | $260.6M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 9 | $266.0M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 8 | $80.3M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 7 | $163.5M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 7 | $154.0M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 9, 2023 | 6 | $162.0M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 8 | $207.2M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 8 | $390.4M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 10, 2022 | 10 | $771.4M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 10 | $820.6M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 27, 2022 | 8 | $699.8M | 13F-HR/A |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 9 | $945.3M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 3 | $20.0M | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 12, 2020 | 4 | $29.7M | 13F-HR |
| Q1 2020 | Mar 31, 2020 | May 6, 2020 | 5 | $59.2M | 13F-HR |
| Q4 2019 | Dec 31, 2019 | Feb 5, 2020 | 5 | $76.7M | 13F-HR |
| Q3 2019 | Sep 30, 2019 | Nov 12, 2019 | 5 | $91.4M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.